Background
Over the past 30 years health care systems in many parts of the world have focused on creating evidence-based guidelines and aligned to these guidelines, measuring quality based on whether certain processes and structures of care have been followed. The end-points in clinical trials that have often been used to inform the development of these guidelines, have largely focused on biomarkers and outcomes like survival. This is part of what the Scottish Chief Medical Officer has identified as “industrialised and transactional care”.
In 2010, the work of Michael Porter, Elizabeth Teisberg and others highlighted that we might be meeting certain standards of care but this does not mean we are achieving the outcomes that matter to people sustainably.[1] This led to a focus on the concept of value – defining the ‘outcomes that matter’, often involving Patient Reported Outcomes (PROs), and relating these to the cost that it takes to achieve them, aiming for the best outcomes at the lowest cost. With this broader focus on the ‘outcomes that matter’, PROs have been increasingly used as endpoints in clinical trials.
However, measuring outcomes, including PROs, in both clinical trials and clinical practice, still does not enable us to understand what actually matters to a particular person, at a specific point in time, in relation to their life and their circumstances. This is the true measure of value.
In 2021, we launched the concept of Person-Centred Value-Based Health Care (PCVBHC), aiming to address the above challenge. PCVBHC emphasises the importance of (i) understanding the values, goals and preferences of individual people, (ii) measuring the extent to which people’s goals have been achieved and preferences respected – in both clinical trials and clinical practice – and (iii) using this data to support assessments of effectiveness and clinical quality.
[1] Porter ME. 2010. What is Value in Health Care? NEJM. 363:2477.
About the Report Launch and Learn Event
Building on the above work, we are thrilled to invite you to the launch of our second Policy Report, focused on the pivotal question: “How can we enable people accessing care and their clinicians to collaborate in a shared goal-setting and decision-making process to align care to personal values, goals and preferences?” This critical topic lies at the heart of making PCVBHC a reality.
Join us for an insightful event where we will unveil the key findings and highlights from the Report. Engage in a dynamic panel discussion featuring global experts as we delve into different perspectives around this question. Gain valuable insights from real-world examples showcasing the enablement of shared goal-setting and decision-making between people accessing care and clinicians.
Additionally, we will explore the evolving role of technology and artificial intelligence in capturing and aggregating people’s values, goals, and preferences such that the data can be used at the meso and macro levels. This is a strategic priority for Sprink and we will share our latest thinking in this area.
Register now to reserve your spot and be part of this transformative conversation.
Why is this Report significant?
As a first step in achieving PCVBHC, we need to understand how we can enable people accessing care and their clinicians to collaborate in a shared goal-setting and decision-making process to align care to people’s personal values, goals and preferences. Whether you are a patient, carer, clinician, health service leader, health service manager, researcher, policy maker, life science company leader, payer – this is relevant to you!
The initial perception of personalising care can seem overwhelming and resource-intensive. This report is strategically designed with the explicit goal of unravelling this apparent complexity and converting it into practical, actionable opportunities for implementation.
Who should attend the Report Launch and Learn Event?
The Report Launch and Learn Event is designed to cater to a diverse audience, including patients, carers, clinicians, health service leaders, health service managers, researchers, policy makers, life science company leaders, payers. We welcome anyone with an interest in advancing Person-Centred Value-Based Health Care!
Report Launch and Learn Event Format and Dates
We will be hosting three online Launch and Learn Events, each lasting 90 minutes, to cater to our global audience. Each Event will feature the same programme but will include different guest speakers. Please see the programme below for more details about the guest speakers. The event dates and times are as follows:
- Tuesday, April 30th at 3:00 am EDT, 8:00 am BST, 9:00 am CEST, 5:00 pm AEST.
- Tuesday, May 7th at 7:00 am EDT, 12:00 pm BST, 1:00 pm CEST, 9:00 pm AEST.
- Wednesday, May 8th at 9:00 am EDT, 2:00 pm BST, 3:00 pm CEST, 11:00 pm AEST.
| Time (BST) | Session | Description | Speaker(s) |
|---|---|---|---|
| 8.00-8.05am. | Welcome and introduction. |
|
|
| 8.05-8.15am. | Overview of the PCVBHC Report key findings. |
|
|
| 8.15-8.45am. | Panel discussion: Facilitating collaborative care. |
|
|
| 8.45-8.55am. | Success stories. |
|
|
| 8.55-9.05am. | Capturing and aggregating people’s values and goals at scale. |
|
|
| 9.05-9.25am. | Questions and discussion between panel and the meeting participants. |
|
|
| 9.25-9.30am. | Closing remarks. |
|
|
| Time (BST) | Session | Description | Speaker(s) |
|---|---|---|---|
| 12.00-12.05pm. | Welcome and introduction. |
|
|
| 12.05-12.15pm. | Overview of the PCVBHC Report key findings. |
|
|
| 12.15-12.45pm. | Panel discussion. |
|
|
| 12.45-12.55pm. | Success stories. |
|
|
| 12.55-1.05pm. | Capturing and aggregating people’s values and goals at scale. |
|
|
| 1.05-1.25pm. | Questions and discussion between panel and the meeting participants. |
|
|
| 1.25-1.30pm. | Closing remarks. |
|
|
| Time (BST) | Session | Description | Speaker(s) |
|---|---|---|---|
| 2.00-2.05pm. | Welcome and introduction. |
|
|
| 2.05-2.15pm. | Overview of the PCVBHC Report key findings. |
|
|
| 2.15-2.45pm. | Panel discussion. |
|
|
| 2.45-2.55pm. | Success stories. |
|
|
| 2.55-3.05pm. | Capturing and aggregating people’s values and goals at scale. |
|
|
| 3.05-3.25pm. | Questions and discussion between panel and the meeting participants. |
|
|
| 3.25-3.30pm. | Closing remarks. |
|
|
Report Launch and Learn Event Guest Speakers
We are privileged to announce that esteemed global experts in this field will be joining us as guest speakers, enriching the discussion with their invaluable insights and experiences.
Thomas Allvin
Executive Director, Strategy and Health Care Systems, European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium.
Thomas Allvin is Executive Director for Strategy and Health care Systems at the European Federation of Pharmaceutical Industries and Associations (EFPIA), where his responsibilities include overall strategic coordination, support to the EFPIA Board and Executive Committee and leading EFPIA’s work on policies for more sustainable, value-based and patient-centric health systems, including patient and stakeholder relations. Before joining EFPIA in 2015, Thomas was Health Counsellor at the Permanent Representation of Sweden to the European Union, representing Sweden in the Council working parties for public health and pharmaceuticals & medical devices, and previously worked in several positions in the Swedish Ministry of Health and the Swedish Parliament.
Karl Arnberg
Global Director Evidence and Access Policy, Novartis, Switzerland.
Throughout his career, Karl has worked in the intersection of evidence, access, and pricing of medicines. Before joining Novartis in 2018, Karl spent 14 years working for the Swedish government on pricing of medicines. In his current role as Global Director Evidence & Access Policy, he is collaborating with stakeholders along the continuum of a medicines’ life cycle to understand how evidentiary requirements impacts patients’ access to medicines.
He is a strong believer in incentives as a mechanism to enable optimal outcomes for patients while ensuring the sustainability of the health-care systems. Person-centered value-based healthcare paired with thoughtful collection and analyses of data can lead not only to better outcomes but also to more efficient resource allocation, addressing some of the major challenges healthcare systems across the world are facing.
Antonella Cardone
Chief Executive Officer, Cancer Patients Europe (PCE), Belgium.
Antonella Cardone joined CPE as CEO at the end of 2022. She is also the Patient Advocacy Expert and Advisor to the Board of Pancreatic Cancer Europe (PCE), the European Multi-Stakeholder Platform of leading and most influential groups of physicians and patients, politicians, journalists, academia, and industry on Pancreatic Cancer. She is the former Director of the European Cancer Patient Coalition (ECPC). She has 25 years of experience working for non-profits in the health, social, and employment sectors. Before ECPC, Antonella was the Executive Director of the Fit for Work Global Alliance, a multi-stakeholder coalition championing health and work policy change. She has previously served as the Director of the Global Smoke-free Partnership of the American Cancer Society, leading a movement of over 100 members to coordinate the development of smoke-free laws in 40 countries. She holds a Master’s in Science and one in Business Administration. She represented ECPC on the Board of All. Can and on the Board of Pancreatic Cancer Europe, in which she was vice-chair.
Magdalena Daccord
Chief Executive Officer, Familial Hypercholesterolemia Europe, Switzerland.
Magdalena Daccord currently serves as Chief Executive of FH Europe, the European network of patient organizations advocating for individuals affected by familial hyperlipidaemias. Before her tenure with FH Europe, Magdalena played a pivotal role at the Women’s Brain Project, a Swiss-based nonprofit dedicated to advancing innovative approaches to women’s brain and mental health. In her capacity as Head of Partnership Development & Operations, she spearheaded the successful organization of the International Forum on Women’s Brain & Mental Health 2019, facilitating collaborative efforts among diverse stakeholders. Magdalena’s expertise in cultivating multidisciplinary partnerships with industry, academia, patient organizations, regulators, and policymakers has been instrumental in driving progress in the field. She has also represented the Women’s Brain Project at prestigious events such as the European Council for a Position Paper launch and the World Health Organization mental health summit. Previously, Magdalena served as Associate Director, Head of Operations at DIA (Drug Information Association), a global nonprofit facilitating collaboration among health care product development stakeholders. In this role, she led a portfolio of over 70 educational and scientific projects across the EMEA region and collaborated closely with regulators, HTAs, patient organizations, and industry associations. Before her tenure at DIA, Magdalena held various roles at Alexion, a global biopharmaceutical company focused on rare diseases.
Kristina Dziekan
Non-Executive Director, ONWARD, Switzerland.
Kristina Dziekan, a Non-Executive Director at ONWARD Medical Technology, is dedicated to revolutionizing treatments for spinal cord injuries, enhancing mobility, independence, and overall health. Serving on the Board and Audit Committee since 2022, Kristina brings a wealth of experience from her tenure as Head of Market Access, Government Affairs, and Tendering at Alcon in Europe.
With over two decades in the life sciences sector, Kristina has consistently championed patient access to innovative treatments grounded in tangible outcomes. Her leadership at Alcon has focused on fostering collaborations with scientific communities, patients, and payers to advance outcomes-based payment models and pioneer value-based procurement strategies. Kristina holds an impressive academic background, including an MSc in Health Policy, Planning, and Financing from the London School of Economics, an MA in International Economics and European Studies from Johns Hopkins University, a BA in Philosophy, Politics, and Economics from Oxford University, and a Vordiplom in Business Administration and Economics from Georg August University.
Chris Lambert
MSK Physiotherapist and Clinical Lead of the Exercise & Lifestyle programme, Swansea Bay University Health Board, Wales, UK.
Chris Lambert earned his Sport & Exercise Science degree from Cardiff University in 2001 before pursuing further studies in Physiotherapy, graduating in 2006. Starting his career at Cardiff & Vale UHB, he specialized in Musculoskeletal (MSK) Physiotherapy by 2009. Alongside his NHS duties, Chris ventured into elite sports, serving as a Physiotherapist at the London 2012 games, with team Wales at the Glasgow 2014 Commonwealth Games, and at the First European Games in Baku 2015.
In 2014, Chris transitioned to Swansea Bay UHB, assuming the role of MSK Advanced Practice Physiotherapist. His involvement in the non-surgical management of Knee Osteoarthritis (OA) began in 2016, initiating a pilot program named the Exercise & Lifestyle Programme (ELP). Prior to its launch in April 2021, ELP evolved into a digital-based service. While continuing his work as an MSK Physiotherapist, Chris currently serves as the clinical lead of the Exercise & Lifestyle Programme. His responsibilities include clinical-based research on the impact of lifestyle interventions on patients with Knee Osteoarthritis.
Dr Thomas Kelley
Chief Executive Officer, Sprink, England, UK.
Thomas Kelley is current CEO of Sprink. Prior to this role, between 2018 and 2019, he was the National Clinical Advisor on Value- Based Health Care (VBHC) for the Welsh Government. Between 2013 and 2018 he worked at the International Consortium for Health Outcomes Measurement (ICHOM). He established the London office in 2014 and subsequently led ICHOM’s work in the EMEA region between 2014 and 2017. In 2017 he took overall responsibility for ICHOM’s day-to-day operations across its London and Boston offices. He also had global responsibility for ICHOM’s strategic partnerships. Prior to working at ICHOM he practiced as a physician at Oxford University Hospitals (OUH). He received his BSc and MD from the University of Manchester, UK and MBA from the University of Oxford, UK.
Dr Martha Kidanemariam (TBC)
PhD Candidate Value Based Health Care, Leiden University Medical Center, The Netherlands.
Martha Kidanemariam is a driven health care professional with a multifaceted background spanning clinical practice, research, and academic pursuits. Currently serving as a Junior Doctor (ANIOS) in Haematology at Erasmus MC, Martha is dedicated to delivering high-quality care to patients while honing her clinical skills in a specialized field. In addition to her clinical role, Martha is pursuing a PhD in Value-Based Health care at Leiden University Medical Centre. Her research interests centre on person-centeredness and shared decision-making, reflecting her commitment to improving health care delivery through patient-focused approaches. Prior to her current positions, Martha gained valuable experience as a Junior Doctor (ANIOS) in Internal Medicine at Maasstad Ziekenhuis, where she provided comprehensive care to patients with diverse medical needs. Martha’s journey in health care began during her medical studies at Erasmus MC, where she developed a strong foundation in medicine and conducted research in vascular and transplantation surgery. She furthered her education with a Master’s degree in Medicine from Erasmus University Rotterdam, during which she explored topics such as emergency care for children with fever and completed an elective internship in Emergency Medicine at Academisch Ziekenhuis Paramaribo.
Carl Lander
Health Care Consultant and Patient Advocacy Leader, England, UK.
Carl Lander is as a Registered Nurse and has worked within both critical care and interventional cardiology specialities. Carl moved into education and then on to organisational development and people advocacy roles; these roles crossed both health care management and, with the Royal College of Nursing, representing and advising nurses on both employment and professional issues. Carl currently works in roles that support NHS Trusts to improve or change systems and processes to resolve issues and seek more effective ways of working, along with Patient Advocacy roles, to support patients with Rare Diseases
His involvement in patient advocacy extends globally, from sitting on the Agios PK Deficiency Advocacy Advisory Council to serving on the global PEAK Registry Steering Committee as a patient representative. Carl’s dedication to improving the patient experience is evident through his collaboration with Metabolic Support UK, where he implements advocacy strategies and recently became a Trustee. Carl’s ultimate goal is to further immerse himself in patient advocacy roles, leveraging his expertise to effect positive change in health care delivery and patient outcomes.
Prof Dr Richard Lehman
Professor of Shared Understanding of Medicine, Institute of Applied Health Research, University of Birmingham, England, UK.
Richard Lehman was Professor of the Shared Understanding of Medicine in the Institute of Applied Health Research at the University of Birmingham until 2020. He was a general practitioner in Banbury for 37 years. For 20 years he compiled a weekly summary of articles from the principal medical journals which was posted on the BMJ website. After retirement from full-time general practice in 2010 he worked initially on studies of patient experiences, and spent a year at Yale University working on patient-centered outcomes and helping to set up the Yale Open Data Access (YODA) project. He remains a consultant to the group.
He was guest editor for the Sharing Medicine series in JAMA Internal Medicine (Sep 2017) and is an editorial adviser for the journal. He retains a keen interest in promoting Value-Based Health Care based on trust and shared understanding.
Prof Dr Sally Lewis
National Clinical Lead for Value-Based and Prudent Health Care, NHS Wales, Wales, UK.
National Clinical Lead for Value-Based Prudent Health Care at NHS Wales and Honorary Professor at Swansea School of Medicine, Value for Health Program Sally has frontline experience of primary care most challenging having been a senior partner and GP trainer in a practice in valleys of Wales.
He began a career in medical management in 2011 and was appointed Assistant Medical Director for Value Based Care at Aneurin Bevan University Health Board in 2014.
Still practicing as a GP, Sally is now the National Clinical Lead for Prudent Health care Based in Wales, and an Honorary Professor at Swansea School of Medicine.
Her current interests include using Value-Based principles to allocate resources in publicly funded systems, patient outcome data and digital transformation.
Thomas Metcalfe (TBC)
Head of Health Care System Partnerships Cluster, Medical Affairs, Roche, Switzerland.
Tom Metcalfe currently serves as the Head of PHC Health care System Partnerships within Roche’s Product Development Medical Affairs organisation. In this role, he spearheads initiatives related to PHC health care partnerships, clinical decision support, Value-Based Health Care, and outcomes innovation within Roche Pharma’s global medical affairs division. Previously, Tom held the position of Data Policy Lead within the Roche Pharma Personalised Healthcare (PHC) Centre of Excellence until March 2019. From March 2015 to March 2018, he served as a Strategic Innovation Leader in Roche Pharma Global Product Development, focusing on Digital Health, Innovative Development Pathways, and the utilisation of comprehensive genomics profiling technologies in cancer medicine development. Tom’s career journey includes serving as Managing Director at Oncotest GmbH, a preclinical CRO specializing in oncology models, before joining Roche. He also spent significant time at Roche Pharma, where he held roles such as Global Head of the Biomarker Programme (2004-2007) and Head of the PHC Portfolio (2007-2010). Prior to his tenure at Roche Pharma, Tom spent a decade at Roche Diagnostics, contributing to various leadership positions in marketing and business development.
Additionally, Tom has been actively involved in industry associations, having chaired the European Biopharmaceutical Enterprises Task Force on Personalised Medicines from 2009 to 2011. Currently, he serves as the Roche Pharma delegate to the European Federation of Pharmaceutical Industry Associations (EFPIA) Innovation Committee. Tom holds a degree in Biochemistry from King’s College, London University, and an MBA from the Open University, UK.
Prof Dr Victor Montori
Robert H. and Susan M. Rewoldt Professor of Endocrinology, Mayo Clinic, and Co-Founder, The Patient Revolution, USA.
Victor Montori holds the position of Professor of Medicine at Mayo Clinic, where he specialises in endocrinology and conducts research on health services. With over 750 peer-reviewed publications to his name, Victor ranks in the top 1% of researchers with the most cited papers in clinical medicine worldwide over the past decade. He serves as a Senior Advisor at the Agency for Health care Quality and Research of the US Government and sits on the Editorial Advisory Board of BMJ. Additionally, Victor serves as Director of Late Stage Translational Research at the Mayo Centre for Clinical and Translational Science. Renowned for his expertise in evidence-based medicine and shared decision-making, he is credited with developing the concept of minimally disruptive medicine. Based in Rochester, Minnesota, Victor works at Mayo Clinic’s Knowledge and Evaluation Research (KER) Unit, where he is dedicated to advancing person-centred care for patients with diabetes and other chronic conditions. He recently authored the book “Why We Revolt – a Patient Revolution for Careful and Kind Care.”
Don Redding
Director of Policy, National Voices, England, UK.
Don Redding is Director of Policy for National Voices, the coalition of charities that stands for people being in control of their health and care. He has led National Voices’ work on integrated care, including the production of five ‘narratives’ demonstrating what people themselves want from ‘person-centred coordinated care’. More recently Don was part of the Realising the Value programme working with NHS England to develop a new articulation of value in health and care, based on what matters most to people and communities. A former social care journalist, Don has worked for leading national voluntary organisations since 1991, and was previously head of policy and communications for Picker Institute Europe.
James Sanderson
Director of Personalised Care, NHS England, England, UK.
James Sanderson is the Director of Personalised Care at NHS England, working within the Strategy and Innovation Directorate to oversee the strategy and delivery for a range of programmes that are helping to empower people to have greater choice and control over their care. This includes the Personal Health Budgets programme, Integrated Personal Commissioning (IPC), Shared Decision Making, Person-Centred Care, Maternity Pioneers and developing and implementing new models of delivering patient choice. James joined NHS England in November 2015, and was formerly Chief Executive and Accounting Officer for the Independent Living Fund (ILF). The ILF was used to support disabled people across the whole of the UK to live independent lives through the provision of direct payments enabling the purchase of personal assistance support. After graduating, James embarked on a career in the private sector before joining the ILF in 2002 to undertake a number of senior roles including Operations Director with responsibility for front line service delivery, and Business Development Director with responsibility for performance development, change management and information governance.
Prof Dr Christobel Saunders
James Stewart Chair of Surgery, University of Melbourne, Australia.
Christobel Saunders is the James Stewart Chair of Surgery, the Head of the Department of Surgery at the University of Melbourne (Royal Melbourne Hospital precinct) and consultant surgeon in the Department of General Surgery at Royal Melbourne Hospital and the Peter MacCallum Cancer Institute. She is internationally recognised as one of Australia’s most prominent research-orientated cancer surgeons. She has substantially contributed to breast cancer research including clinical trials of new treatments, psychosocial, translational and health services research. In recognition of her sustained career excellence and innovation, she has been publicly acknowledged through numerous awards and honours including Order of Australia 2018, the Uccio Querci della Rovere Award (2018), WA Women’s Hall of Fame Inductee (2018), WA Scientist of the Year (2017) and Cancer Council WA career Achievement Award (2021).
Siân Slade
Enterprise Fellow (Honorary), University of Melbourne, and Founder & Chair, #NavigatingHealth Project, Australia.
Siân Slade, a UK-trained pharmacist with qualifications in MPH, MBA, and GAICD, serves as an Enterprise Fellow (Honorary) at the University of Melbourne. With extensive experience in pharmacy and pharmaceutical leadership spanning the UK, France, the USA, and Australia, Siân has specialized in research, development, and commercialization, focusing on global and regional capabilities in content, knowledge, and medical information. Motivated by her involvement in HIV/AIDS initiatives and her MPH studies, Siân’s interest in global health systems led her to pursue research on patient navigation in health care. Her PhD, in collaboration with the University of Melbourne and Swansea University/Welsh Value in Health Centre, explores mechanisms enabling patients to navigate health care in Australia and Wales. Siân’s commitment to public health extends to her contributions to various media platforms and her book chapter on managing knowledge in the pharmaceutical industry. She founded #NavigatingHealth, a social impact project, and chairs the National Network with the Australian Disease Management Association. Additionally, Siân serves on the boards of several organizations in Australia and co-chairs the International Social Prescribing Collaborative Steering Group, advocating for health integration across sectors.
Kathryn South
Head of Person-Centred Care, Welsh Value in Health Centre, Wales, UK.
Kathryn is the Head of Person-Centred Care” for the Welsh Value in Health Centre. She brings over 26 years of experience working within the NHS, with the past 15 years spent at a Senior Management level both locally and nationally. She has effectively managed a diverse portfolio of responsibilities, including Research & Development, Public Engagement, Patient Experience, Volunteering, Chaplaincy, Patient Information/Patient Stories, PALS Service, Concern PTR Team, Armed Forces Personnel/Veterans, and Programme Management. Her expertise extends to national-level work, where she has been instrumental in developing strategies and frameworks with local impact. Kathryn has successfully represented Cwm Taf Health Board on Welsh Government Project Boards, co-chaired the WG Patient Experience Group, and participated in a patient experience collaboration hosted by North Cumbria. Notably, she led a 12-month real-time patient feedback initiative, earning recognition for her and the Patient Advice and Liaison Service (PALS) Team’s contributions, as well as being nominated as runners-up in the Patient Experience Network National Awards for locally implemented initiatives. For the past three years, Kathryn has played a crucial role in supporting the Maternity Improvement Team under special measures, initially as Programme Manager and subsequently as the Experience & Engagement Lead since March 2022. In this capacity, she has overseen the progression of RCOG 70 recommendations, facilitated staff engagement, supported the development of robust engagement plans, culture & leadership plans, and maternity vision & strategy, while effectively managing project teams.
Dr Andrea Srur
Associate Director, Global Centre of Excellence in Person-Centred Value-Based Health Care, Sprink, England, UK.
Andrea Srur is a Medical Doctor trained in Chile at Universidad Mayor. Following her training, she completed a MSc in Management and Organisational Innovation at Queen Mary University London (2012) and a MSc in Health Systems and Global Policies (2018) at Queen Mary University London. She was Head of the Non-Communicable Diseases Department at the Ministry of Health in Chile, working on NCD policies, strengthening the national network and bringing stakeholders together, and through what she developed an interest for Value-Based Health Care and joined the International Consortium for Health Outcomes Measurement (ICHOM) in London in 2016 as Outcomes, Analytics and Benchmarking Manager. At ICHOM Andrea supported the implementation of Value-Based Health Care in hospitals across the UK, Europe and South America. After ICHOM, and during the pandemic, Andrea was the Programme Manager of the National Children Diabetes Quality Improvement Programme for England and Wales at the Royal College of Paediatrics and Child Health (RCPCH) in London, UK. Since 2022, Andrea is the Associate Director for the Global Centre for Person-Centred Value-Based Health Care, managed by Sprink.
Prof Anne Stiggelbout
Professor of Medical Decision Making, Leiden University Medical Center and Erasmus School of Health Policy and Management, The Netherlands.
Anne Stiggelbout is professor of Medical Decision Making at Leiden University Medical Center and at the Erasmus School of Health Policy and Management. Her research and teaching relate to individual doctor-patient decision making as well as Value-Based Health care. This research involves doctor-patient communication, including risk communication, as a constituent of shared decision making.
Recently she embarked on research on carepath redesign to empower both doctors and patients (and their decision partners) in Shared Decision making. Her research is both methods- and implementation-focused. Further normative and ethical aspects of medical decision making are topic of this line of research. She has received many grants from among others the Dutch Cancer Society and the Netherlands Organisations for Scientific Research (NWO, incl. a VIDI grant) and Medical Research (ZonMw), on patient preference assessment, patient empowerment, and shared decision-making and risk communication.
She is active in implementing Shared Decision Making locally, regionally, and nationally in the Netherlands. Her group has developed both eLearning and training workshops for professionals for this purpose. She is program lead of the Scientific Research Program on Value-Based Health care of the LUMC. Anne is active in scientific advisory committees and boards in the area of medical decision making.
Prof Dr Mary Tinetti
Gladys Phillips Crofoot Professor of Medicine (Geriatrics), Yale School of Medicine, USA.
Mary Tinetti is a geriatrician focused on helping patients with multiple health conditions receive well-rounded care, as well as weigh the benefits and harms of commonly used medicines. Mary is at the forefront of a nationwide effort to develop and test an approach to health care that aligns clinical care and decision-making with specific priorities of older adults with multiple health problems. This involves assisting patients in identifying their most important health goals and teaching clinicians to translate these goals into care decisions. She is also evaluating how feasible this approach is for clinical care and its effect on patient outcomes. In her research, Mary and her team helped identify the causes, consequences, and prevention of fall injuries in older adults and translated these findings into clinical and public health practice. The National Institutes of Health (NIH) and several foundations fund Mary’s work, and she has published more than 250 peer-reviewed articles. She has received numerous awards, is a member of the National Academy of Medicine, and is the recipient of a MacArthur Foundation fellowship.
Prof Dr Angelique van Weel
Professor Erasmus University Rotterdam, Rheumatologist and Dean Science, Maasstad Hospital, The Netherlands.
Prof. Dr. Angelique E.A.M. Weel-Koenders is a distinguished professional with a comprehensive background in rheumatology, management, and clinical research. She started her medical career at the Free University in Amsterdam and subsequently conducted clinical research at Erasmus MC, leading to her 2001 thesis on “Genetic and Skeletal Determinants of Osteoporosis.” Completing her rheumatology training in 2006, she focused on inflammatory arthritis treatment strategies, resulting in peer-reviewed publications. Besides clinical work, from 2010 until 2020 she served on the medical board at the Maasstad Hospital, a large trainee hospital in Rotterdam the Netherlands. In 2016, she founded JOINT VALUE, an integrated practice network aimed at improving value throughout the patient journey in inflammatory arthritis. She has been instrumental in implementing Value-Based Healthcare (VBHC) principles at the Maasstad Hospital, a SANTEON Hospital. She contributed to the ICHOM working group in 2018, introducing Patient-Reported Outcome Measures (PROMs) for arthritis patients. JOINT VALUE received the VBHC Collaboration Prize in 2020 for implementing VBHC principles at the micro, meso, and macro levels. Since January 2019, she has held the position of Professor at the Erasmus University (Erasmus School of Health Policy & Management, section HTA) focusing on ‘Evidence-Based Value Creation in Patient Care,’ showcasing her commitment to advancing healthcare practices and policies from a value-based perspective.
Vincent Wiersma
Value-Based Health Care Specialist, Amgen, The Netherlands.
Vincent Wiersma is a Value-Based Health Care (VBHC) Manager at Amgen, collaborating alongside Amgen’s Director of Value, Access, & Policy, to pioneer advancements in patient-centred care. With over five years of experience in the health care sector, Vincent’s expertise lies in driving value-driven initiatives that prioritise patient outcomes. At Amgen, Vincent and his team have redefined the landscape of partnerships, emphasising equality, trust, and value-driven approaches. Through co-creation initiatives with hospitals, they strive to achieve the best possible outcomes for patients. Vincent’s vision aligns with Amgen’s goal of being reimbursed based on the value their treatments bring to patient-relevant outcomes, a mission he actively supports by leveraging in-house expertise to measure and improve health care outcomes. Prior to his role at Amgen, Vincent served as a Health Care Consultant at The Decision Group, where he honed his skills and expertise in devising strategic solutions to optimise health care delivery and outcomes. Vincent’s journey into the health care sector began with his academic pursuits. He completed his bachelor’s degree in Biomedical Sciences at the University of Amsterdam, where he laid the foundation for his understanding of medical sciences. Eager to bridge the gap between the medical world and the business sector, Vincent pursued a master’s degree in Science & Business Management at Utrecht University. This interdisciplinary program empowered him to integrate his knowledge of healthcare with business acumen, preparing him for the multifaceted challenges of the industry.
Report Launch and Learn Event Registration Fees
All proceeds generated from the Report Launch and Learn Events will be allocated towards furthering research in the PCVBHC field, with the findings made openly accessible. Additionally, funds will be used to offer scholarships to full-time undergraduate or postgraduate students, as well as patients or patient representatives, to participate in the Global Centre’s PCVBHC Training Programme.
| Category | Definition | Fee |
|---|---|---|
| Members of the Global Centre of Excellence in PCVBHC. |
| No fee. |
| Students and patient advocacy organisations*. |
| No fee. |
| Concession. |
| £50. |
| Multiple (Concession). |
| £35. |
| Regular. |
| £150. |
| Multiple (Regular). |
| £100. |
*For students and patient advocacy organisations, please get in touch with Andrea Srur at a.srur@sprink.co.uk to provide proof of your status for complimentary access to the Launch and Learn Event.
